Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
160Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.88B | $591.92M | $15.29 |
| 2024 | $3.00B | $378.28M | $9.86 |
| 2023 | $2.44B | $255.48M | $6.71 |
| 2022 | $2.78B | $476.52M | $12.15 |
| 2021 | $3.31B | $740.12M | $18.48 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $3.49 per share
Typical surprise +33.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$2.91 vs $3.03miss
- Wed, Apr 29$7.53 vs $5.43beat
- Wed, Feb 4$5.13 vs $3.83beat
- Wed, Oct 29$3.48 vs $3.25beat
- Wed, Jul 30$2.42 vs $1.78beat
- Wed, Apr 30$3.49 vs $1.54beat
Estimates and results for EVR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from EVR's reported EPS growth of -4.6% a year over 4 years.
- EPS in 5 years
- $10.54
- Implied price
- $231.86
- Return from $307.38
- -5.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $115.28 — -62.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -14.6% | -20.6% | -17.8% | -15.4% | -13.2% | -11.2% |
| -9.6% | -16.0% | -13.0% | -10.4% | -8.1% | -6.0% |
| -4.6% | -11.3% | -8.2% | -5.5% | -3.0% | -0.8% |
| 0.4% | -6.7% | -3.4% | -0.5% | 2.0% | 4.4% |
| 5.4% | -2.0% | 1.4% | 4.4% | 7.1% | 9.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- News (RSS)financialpost·1d ago·Positive
Evolve Royalties Announces Results of Annual and Special Meeting of Shareholders VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) — Evolve Royalties Ltd. (“Evolve” or the “Company”) (CSE: EVR; OTCQX: EVRYF) is pleased to announce that at its annual and special meeting of shareholders held earlier today (the “Meeting”), Evolve’s shareholders elected Joseph de la Plante, Vincent Metcalfe, Elif Lévesque, Mathieu Gignac and Fraser Laschinger as […]
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company's management will participate in…
View source ↗ - News (RSS)investing.com·5d ago·Neutral
Evercore sees July asset manager flows improve on ETF demand
View source ↗